Zdenek Sumnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zdenek Sumnik has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Ondrej Cinek
Charles University in Prague, University Hospital Motol and Homolka
38 shared publications - Jan Lebl
Department of Paediatrics, 2nd Faculty of Medicine, Charles University In Prague and Motol University Hospital, Prague, Czech Republic
37 shared publications Stanislava Kolouskova
17 shared publications- Stanislava Kolouskova
Department of Paediatrics, 2nd Faculty of Medicine, Charles University, Prague, Czechia
15 shared publications - Barbora Obermannova
Department of Paediatrics, 2nd Faculty of Medicine, Charles University, Prague, Czechia
11 shared publications Barbora Obermannova
Department of Pediatrics, Motol University Hospital and 2 Faculty of Medicine, Prague, Czechia
10 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Population‐Based Screening for Type 1 Diabetes in Czechia: Results From the First 1% of the Paediatric Population
Aims: EDENT1FI is a European initiative aiming to implement a roadmap for screening, monitoring and prevention of childhood Type 1 diabetes (T1D). The Betty project is a nationwide T1D screening program recently established in Czechia within the framework of EDENT1FI. Here we report its results after having tested 1% of the Czech paediatric population. Methods: The screening targets children aged 2–17.9 years, regardless of whether they have a family history of T1D. It follows a two‐step process for detecting islet‐specific autoantibodies (anti‐GAD, anti‐IA2, anti‐ZnT8 and IAA). If the capillary screening sample is positive in the first‐level test (screening ELISA yielding a summary signal of three autoantibodies), the same sample is retested at the EDENT1FI reference laboratory using a battery of 4 second‐level tests for individual autoantibodies (LIPS or RBA). When any autoantibody is detected, a venous sample is requested for confirmation. If multiple autoantibodies are confirmed from this venous sample, the child is diagnosed with early‐stage T1D and offered follow‐up tailored to their individual estimated rate of progressing to clinical diabetes. Children with only a single confirmed autoantibody are offered a less intensive follow‐up outside the EDENT1FI protocol. Results: The Betty project collected 19 044 capillary screening samples (1% of the paediatric population) between April 2024 and February 2026. Samples were collected across 270 screening sites mostly at primary care and via home sampling (4.1% samples). The majority of participants (89.7%) were from the general population having no first‐degree relative (FDR) with T1D. We found a prevalence of multiple autoantibodies of 0.39% (95% CI: 0.30%–0.51%) in the general population and 2.8% (95% CI: 2.1%–3.7%) prevalence among FDRs of subjects with T1D. At the time of writing, of 201 children with non‐negative capillary screening sample, 102 were diagnosed with early‐stage T1D by a confirmatory venous sample and 83 had their T1D stage assessed: 77 (93%) were in Stage 1, 4 (4.8%) in Stage 2 and 2 (2.4%) in Stage 3. Further seven children, who were identified by capillary screening, manifested with Stage 3 T1D before their staging could be completed. All families who came for staging and education visits consented to long‐term follow‐up. Conclusions: This nationwide T1D screening program successfully reached approximately 1% of the Czech paediatric population, demonstrating the feasibility of implementing population‐based islet autoantibody screening based on the common EDENT1FI protocol. These findings provide an important foundation for the potential future implementation of routine population‐based T1D screening within the Czech national healthcare system and offer valuable insights for other countries considering similar screening programmes.
- 27 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessPopulation‐Based Screening for Type 1 Diabetes in Czechia: Results From the First 1% of the Paediatric Population
Aims: EDENT1FI is a European initiative aiming to implement a roadmap for screening, monitoring and prevention of childhood Type 1 diabetes (T1D). The Betty project is a nationwide T1D screening program recently established in Czechia within the framework of EDENT1FI. Here we report its results after having tested 1% of the Czech paediatric population. Methods: The screening targets children aged 2–17.9 years, regardless of whether they have a family history of T1D. It follows a two‐step process for detecting islet‐specific autoantibodies (anti‐GAD, anti‐IA2, anti‐ZnT8 and IAA). If the capillary screening sample is positive in the first‐level test (screening ELISA yielding a summary signal of three autoantibodies), the same sample is retested at the EDENT1FI reference laboratory using a battery of 4 second‐level tests for individual autoantibodies (LIPS or RBA). When any autoantibody is detected, a venous sample is requested for confirmation. If multiple autoantibodies are confirmed from this venous sample, the child is diagnosed with early‐stage T1D and offered follow‐up tailored to their individual estimated rate of progressing to clinical diabetes. Children with only a single confirmed autoantibody are offered a less intensive follow‐up outside the EDENT1FI protocol. Results: The Betty project collected 19 044 capillary screening samples (1% of the paediatric population) between April 2024 and February 2026. Samples were collected across 270 screening sites mostly at primary care and via home sampling (4.1% samples). The majority of participants (89.7%) were from the general population having no first‐degree relative (FDR) with T1D. We found a prevalence of multiple autoantibodies of 0.39% (95% CI: 0.30%–0.51%) in the general population and 2.8% (95% CI: 2.1%–3.7%) prevalence among FDRs of subjects with T1D. At the time of writing, of 201 children with non‐negative capillary screening sample, 102 were diagnosed with early‐stage T1D by a confirmatory venous sample and 83 had their T1D stage assessed: 77 (93%) were in Stage 1, 4 (4.8%) in Stage 2 and 2 (2.4%) in Stage 3. Further seven children, who were identified by capillary screening, manifested with Stage 3 T1D before their staging could be completed. All families who came for staging and education visits consented to long‐term follow‐up. Conclusions: This nationwide T1D screening program successfully reached approximately 1% of the Czech paediatric population, demonstrating the feasibility of implementing population‐based islet autoantibody screening based on the common EDENT1FI protocol. These findings provide an important foundation for the potential future implementation of routine population‐based T1D screening within the Czech national healthcare system and offer valuable insights for other countries considering similar screening programmes.
- Open Access
- 12 October 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (12) , 103390
Does macrolide resistance play a role in the clinical outcome of patients with Mycoplasma pneumoniae infection?
- 12 October 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (12) , 103390
Open AccessDoes macrolide resistance play a role in the clinical outcome of patients with Mycoplasma pneumoniae infection?
- Open Access
- 10 September 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (12) , 3501-3511
Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial
Aims/hypothesis: In the PROTECT randomised trial, teplizumab demonstrated significantly greater beta cell function preservation vs placebo in the intent-to-treat (ITT) population. Analyses of the pre-specified per-protocol (PP) population and PP subgroups are presented to further evaluate the efficacy of teplizumab. Methods: Participants aged 8–17 years with stage 3 type 1 diabetes with a peak stimulated C-peptide level ≥0.2 nmol/l (ITT population: N =328) were randomised 2:1 to receive two 12-day courses of teplizumab or placebo intravenously. Participants with n =180; placebo, n =95). At week 78, the primary endpoint of the least squares (LS) mean difference in change of stimulated C-peptide concentration from baseline between teplizumab and placebo was 0.14 nmol/l (95% CI 0.10, 0.18; p −1 day −1 ; 95% CI –0.26, –0.08; p p <0.05) vs placebo. In subgroup analyses, treatment with teplizumab resulted in higher C-peptide levels compared with placebo, regardless of HLA-DR3/HLA-DR4 presence or baseline type 1 diabetes autoantibodies. Conclusions/interpretation: Teplizumab treatment per protocol led to greater beta cell function preservation, greater TIR and lower exogenous insulin use compared with placebo. Beta cell function preservation was maintained irrespective of HLA subtype or the presence of type 1 diabetes autoantibodies. Trial registration: ClinicalTrials.gov NCT03875729 Funding: The study was funded by Provention Bio, a Sanofi company
- 10 September 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (12) , 3501-3511
Open AccessPreserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial
Aims/hypothesis: In the PROTECT randomised trial, teplizumab demonstrated significantly greater beta cell function preservation vs placebo in the intent-to-treat (ITT) population. Analyses of the pre-specified per-protocol (PP) population and PP subgroups are presented to further evaluate the efficacy of teplizumab. Methods: Participants aged 8–17 years with stage 3 type 1 diabetes with a peak stimulated C-peptide level ≥0.2 nmol/l (ITT population: N =328) were randomised 2:1 to receive two 12-day courses of teplizumab or placebo intravenously. Participants with n =180; placebo, n =95). At week 78, the primary endpoint of the least squares (LS) mean difference in change of stimulated C-peptide concentration from baseline between teplizumab and placebo was 0.14 nmol/l (95% CI 0.10, 0.18; p −1 day −1 ; 95% CI –0.26, –0.08; p p <0.05) vs placebo. In subgroup analyses, treatment with teplizumab resulted in higher C-peptide levels compared with placebo, regardless of HLA-DR3/HLA-DR4 presence or baseline type 1 diabetes autoantibodies. Conclusions/interpretation: Teplizumab treatment per protocol led to greater beta cell function preservation, greater TIR and lower exogenous insulin use compared with placebo. Beta cell function preservation was maintained irrespective of HLA subtype or the presence of type 1 diabetes autoantibodies. Trial registration: ClinicalTrials.gov NCT03875729 Funding: The study was funded by Provention Bio, a Sanofi company
- Open Access
- 5 May 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-11
Muscle Function and Bone Strength in Children and Adolescents with Tall Stature
Introduction: Muscle functions are dependent on age, weight, and height. The question of how the muscle-bone unit is adapted for tall stature (TS) is yet to be elucidated. The aim of this study was to evaluate muscle functions and markers of bone strength in children and adolescents with TS. Methods: A total of 98 children and adolescents participated in the study and were divided into two groups: the TS group included 63 non-trained participants (mean age 13.4 ± 3.2 years, height Z-score 3.0 ± 0.7); the basketball players (BPs) group included 35 actively training BPs (mean age 16.8 ± 1.9 years, height Z-score 2.7 ± 0.4). Dynamic muscle functions – relative muscle power (Pmax/mass) and force (Fmax/body weight) – were assessed using jumping mechanography and compared between groups. Parameters of bone strength were assessed in the TS group using peripheral quantitative computed tomography and dual-energy X-ray absorptiometry (DXA). Results: Z-scores of Pmax/mass and Fmax/body weight were significantly decreased in the TS group compared with age- and sex-specific normative values (mean −1.28 ± 1.15; p < 0.001, and −1.10 ± 1.06; p < 0.001), but increased in the BP group (mean 0.99 ± 1.15; p < 0.001 and 0.64 ± 1.42; p < 0.05). Children in the TS group had decreased cortical bone mineral density (BMD) and cortical thickness (mean Z-scores −0.78 ± 1.0 and −0.57 ± 1.12; p < 0.001 for both). Trabecular BMD was normal (mean Z-score 0.31 ± 1.46; p = 0.14) and the stress-strain index was increased (1.93 ± 0.96; p < 0.001). Z-scores of lumbar spine BMD and whole-body bone mineral content (BMC) measured by DXA were increased (0.99 ± 1.22; p < 0.001; 1.81 ± 1.04; p < 0.001), whereas whole-body BMD was normal (0.19 ± 1.16; p = 0.24). Conclusion: Dynamic muscle functions relative to body mass are decreased in healthy untrained individuals with TS, unlike trained individuals with TS. Reduced mechanical stimulation may contribute to decreased cortical BMD and thickness at the tibia in this group.
- 5 May 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-11
Open AccessMuscle Function and Bone Strength in Children and Adolescents with Tall Stature
Introduction: Muscle functions are dependent on age, weight, and height. The question of how the muscle-bone unit is adapted for tall stature (TS) is yet to be elucidated. The aim of this study was to evaluate muscle functions and markers of bone strength in children and adolescents with TS. Methods: A total of 98 children and adolescents participated in the study and were divided into two groups: the TS group included 63 non-trained participants (mean age 13.4 ± 3.2 years, height Z-score 3.0 ± 0.7); the basketball players (BPs) group included 35 actively training BPs (mean age 16.8 ± 1.9 years, height Z-score 2.7 ± 0.4). Dynamic muscle functions – relative muscle power (Pmax/mass) and force (Fmax/body weight) – were assessed using jumping mechanography and compared between groups. Parameters of bone strength were assessed in the TS group using peripheral quantitative computed tomography and dual-energy X-ray absorptiometry (DXA). Results: Z-scores of Pmax/mass and Fmax/body weight were significantly decreased in the TS group compared with age- and sex-specific normative values (mean −1.28 ± 1.15; p < 0.001, and −1.10 ± 1.06; p < 0.001), but increased in the BP group (mean 0.99 ± 1.15; p < 0.001 and 0.64 ± 1.42; p < 0.05). Children in the TS group had decreased cortical bone mineral density (BMD) and cortical thickness (mean Z-scores −0.78 ± 1.0 and −0.57 ± 1.12; p < 0.001 for both). Trabecular BMD was normal (mean Z-score 0.31 ± 1.46; p = 0.14) and the stress-strain index was increased (1.93 ± 0.96; p < 0.001). Z-scores of lumbar spine BMD and whole-body bone mineral content (BMC) measured by DXA were increased (0.99 ± 1.22; p < 0.001; 1.81 ± 1.04; p < 0.001), whereas whole-body BMD was normal (0.19 ± 1.16; p = 0.24). Conclusion: Dynamic muscle functions relative to body mass are decreased in healthy untrained individuals with TS, unlike trained individuals with TS. Reduced mechanical stimulation may contribute to decreased cortical BMD and thickness at the tibia in this group.
- Open Access
- 24 January 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (2) , 102
Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort
The variety of genes associated with Noonan syndrome spectrum disorders (NSSD) is expanding, and real-life experience with its management is increasing; however, phenotypic differences among genotypes remain poorly defined. We aimed to assess clinical characteristics and response to growth hormone (GH) therapy in a genetically confirmed, single-country multicentre NSSD cohort. We included 101 patients with NSSD (56 males) from six centres: 76 with (likely) pathogenic PTPN11 variants, 7 with SOS1 variants, and 18 with other gene variations. All completed at least one year of GH therapy; 23 reached final height. Parental heights were below average (fathers: − 0.33 SDS [− 1.19; 0.39], p < 0.01; mothers: − 0.68 SDS [− 1.47; 0.12], p < 0.001; medians [IQR]). SOS1-NS patients were born earlier (gestational week 36 [31; 37]) compared to PTPN11 -NS. Birth length (− 1.23 SDS [− 1.74; − 0.57]) was more reduced than weight (− 0.29 SDS [− 1.10; 0.54]; p < 0.0001); PTPN11- NS /SOS1 -NS had the lowest birth weights ( p < 0.05). GH was started at 6.4 years (3.8; 9.5), with baseline height-SDS − 2.92 (− 3.64; − 2.47). Median annual height-SDS increments were similar across genotypes: 0.61 (year 1; n = 101), 0.28 (year 2; n = 92), 0.21 (year 3; n = 77), 0.07 (year 4; n = 63), and 0.09 (year 5; n = 41), leading to height-SDS − 1.97 (− 2.81; − 1.42) after 5 years. Menarche occurred at age 15.7 (13.8; 17.2) years ( n = 13), and final height-SDS (available in 23 patients) reached − 1.68 (− 2.65; − 0.41). Conclusions Growth restriction in NSSD begins prenatally, especially in PTPN11-NS and SOS1-NS. GH therapy was associated with improved height SDS, with the largest height gains observed before puberty. Earlier treatment initiation may therefore be beneficial for growth outcomes. What is Known: • Noonan syndrome spectrum disorders (NSSD) are genetically heterogeneous, with pathogenic variants in the PTPN11 and SOS1 genes being most prevalent. Phenotypic differences among genotypes remain poorly defined. • Short stature is a key NSSD feature. Growth hormone (GH) therapy is beneficial, but prior studies lacked genetic justification or had limited sample sizes. What is New: • We analysed perinatal data and real-life GH outcomes in 101 genetically confirmed NSSD cases. • SOS1-NS was linked to prematurity. Birth length was more reduced than weight across genotypes; PTPN11/SOS1 cases had the lowest birth weights. GH therapy was associated with an increase in height SDS from − 2.92 to − 1.97 (median) following 5 years, and to − 1.68 in those with final height.
- 24 January 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (2) , 102
Open AccessNoonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort
The variety of genes associated with Noonan syndrome spectrum disorders (NSSD) is expanding, and real-life experience with its management is increasing; however, phenotypic differences among genotypes remain poorly defined. We aimed to assess clinical characteristics and response to growth hormone (GH) therapy in a genetically confirmed, single-country multicentre NSSD cohort. We included 101 patients with NSSD (56 males) from six centres: 76 with (likely) pathogenic PTPN11 variants, 7 with SOS1 variants, and 18 with other gene variations. All completed at least one year of GH therapy; 23 reached final height. Parental heights were below average (fathers: − 0.33 SDS [− 1.19; 0.39], p < 0.01; mothers: − 0.68 SDS [− 1.47; 0.12], p < 0.001; medians [IQR]). SOS1-NS patients were born earlier (gestational week 36 [31; 37]) compared to PTPN11 -NS. Birth length (− 1.23 SDS [− 1.74; − 0.57]) was more reduced than weight (− 0.29 SDS [− 1.10; 0.54]; p < 0.0001); PTPN11- NS /SOS1 -NS had the lowest birth weights ( p < 0.05). GH was started at 6.4 years (3.8; 9.5), with baseline height-SDS − 2.92 (− 3.64; − 2.47). Median annual height-SDS increments were similar across genotypes: 0.61 (year 1; n = 101), 0.28 (year 2; n = 92), 0.21 (year 3; n = 77), 0.07 (year 4; n = 63), and 0.09 (year 5; n = 41), leading to height-SDS − 1.97 (− 2.81; − 1.42) after 5 years. Menarche occurred at age 15.7 (13.8; 17.2) years ( n = 13), and final height-SDS (available in 23 patients) reached − 1.68 (− 2.65; − 0.41). Conclusions Growth restriction in NSSD begins prenatally, especially in PTPN11-NS and SOS1-NS. GH therapy was associated with improved height SDS, with the largest height gains observed before puberty. Earlier treatment initiation may therefore be beneficial for growth outcomes. What is Known: • Noonan syndrome spectrum disorders (NSSD) are genetically heterogeneous, with pathogenic variants in the PTPN11 and SOS1 genes being most prevalent. Phenotypic differences among genotypes remain poorly defined. • Short stature is a key NSSD feature. Growth hormone (GH) therapy is beneficial, but prior studies lacked genetic justification or had limited sample sizes. What is New: • We analysed perinatal data and real-life GH outcomes in 101 genetically confirmed NSSD cases. • SOS1-NS was linked to prematurity. Birth length was more reduced than weight across genotypes; PTPN11/SOS1 cases had the lowest birth weights. GH therapy was associated with an increase in height SDS from − 2.92 to − 1.97 (median) following 5 years, and to − 1.68 in those with final height.
- Open Access
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (8) , e2528933
Global Inequities in Diabetes Technology and Insulin Access and Glycemic Outcomes
Importance: Advanced diabetes technologies such as continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (insulin pumps [CSII]), and glucometers alongside insulin access represent the criterion standard for managing type 1 diabetes (T1D) in children. Global disparities in their access and reimbursement may be associated with glycemic outcomes.Objective: To describe how accessibility and reimbursement of advanced diabetes technologies and insulin are associated with glycated hemoglobin (HbA1c) levels in centers participating in the SWEET initiative, an international pediatric diabetes registry.Design, Setting, and Participants: This global multicenter cross-sectional study collected data from 81 centers in 56 countries. Web-based questionnaires were distributed to representatives of all 121 pediatric diabetes centers participating in the SWEET initiative from March 1 to May 31, 2024, and used to map accessibility of and reimbursement for CGM, CSII, glucometers, and insulin. Reimbursement data were compared with HbA1c levels using the SWEET Study dataset. Participants included 42 349 children with T1D.Exposures: Responses were categorized into 4 groups based on the extent of reimbursement for diabetes technologies and insulin.Main Outcomes and Measures: Mean HbA1c levels across centers calculated from measurements current as of December 31, 2023, analyzed by categories of accessibility of and reimbursement for diabetes technologies and insulin.Results: Data collected from 81 of 121 SWEET centers (67%) across 56 countries included HbA1c levels from 42 349 children with T1D (22 021 male [52%]; mean [SD] age, 14.3 [4.4] years; mean [SD] diabetes duration, 6.0 [4.2] years). Universal access with complete reimbursement for all technologies and insulin was reported by 32 centers from 19 countries, while 8 countries reported no reimbursement for any technologies or insulin. Centers with full reimbursement for CSII, CGM, glucometers, and insulin showed mean HbA1c levels of 7.62% (95% CI, 7.59%-7.64%) to 7.75% (95% CI, 7.73%-7.77%) compared with 9.65% (95% CI, 9.55%-9.71%) to 10.49% (95% CI, 10.40%-10.58%) in centers with no reimbursement and/or no availability (P < .001 for all items).Conclusions and Relevance: This cross-sectional study found that HbA1c levels were associated with the accessibility of modern diabetes technologies and insulin. Efforts to ensure universal accessibility are required to reduce global inequities and glycemic outcomes for children with T1D.
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (8) , e2528933
Open AccessGlobal Inequities in Diabetes Technology and Insulin Access and Glycemic Outcomes
Importance: Advanced diabetes technologies such as continuous glucose monitoring (CGM), continuous subcutaneous insulin infusion (insulin pumps [CSII]), and glucometers alongside insulin access represent the criterion standard for managing type 1 diabetes (T1D) in children. Global disparities in their access and reimbursement may be associated with glycemic outcomes.Objective: To describe how accessibility and reimbursement of advanced diabetes technologies and insulin are associated with glycated hemoglobin (HbA1c) levels in centers participating in the SWEET initiative, an international pediatric diabetes registry.Design, Setting, and Participants: This global multicenter cross-sectional study collected data from 81 centers in 56 countries. Web-based questionnaires were distributed to representatives of all 121 pediatric diabetes centers participating in the SWEET initiative from March 1 to May 31, 2024, and used to map accessibility of and reimbursement for CGM, CSII, glucometers, and insulin. Reimbursement data were compared with HbA1c levels using the SWEET Study dataset. Participants included 42 349 children with T1D.Exposures: Responses were categorized into 4 groups based on the extent of reimbursement for diabetes technologies and insulin.Main Outcomes and Measures: Mean HbA1c levels across centers calculated from measurements current as of December 31, 2023, analyzed by categories of accessibility of and reimbursement for diabetes technologies and insulin.Results: Data collected from 81 of 121 SWEET centers (67%) across 56 countries included HbA1c levels from 42 349 children with T1D (22 021 male [52%]; mean [SD] age, 14.3 [4.4] years; mean [SD] diabetes duration, 6.0 [4.2] years). Universal access with complete reimbursement for all technologies and insulin was reported by 32 centers from 19 countries, while 8 countries reported no reimbursement for any technologies or insulin. Centers with full reimbursement for CSII, CGM, glucometers, and insulin showed mean HbA1c levels of 7.62% (95% CI, 7.59%-7.64%) to 7.75% (95% CI, 7.73%-7.77%) compared with 9.65% (95% CI, 9.55%-9.71%) to 10.49% (95% CI, 10.40%-10.58%) in centers with no reimbursement and/or no availability (P < .001 for all items).Conclusions and Relevance: This cross-sectional study found that HbA1c levels were associated with the accessibility of modern diabetes technologies and insulin. Efforts to ensure universal accessibility are required to reduce global inequities and glycemic outcomes for children with T1D.
- Open Access
- 17 June 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (7) , 1-9
Cytogenetic anomalies are the predominant genetic alteration in children with nonfamilial tall stature: a comparative study with familial cases
The purpose of this study is to elucidate the genetic causes and phenotypic presentation of nonfamilial tall stature (nFTS) and to compare these findings with those of familial tall stature (FTS) from the same population that was previously studied. Children with nFTS (defined as a height > + 2 SDs with both parents’ heights < + 2 SDs) underwent endocrine and anthropometric examinations and genetic testing (karyotyping, SHOX gene dosage analysis and next-generation sequencing of 786 growth-associated genes). Exome sequencing was performed in patients with negative genetic results and a height > + 3 SDs. A total of 55 children with nFTS were enrolled. The median height was + 2.8 SD (2.4–3.2 SD), and the median midparental height was + 0.7 SD (0.4–0.9 SD). Genetic causes of tall stature were identified in 6/55 (11%) children. Specifically, four children had gonosomal aneuploidy (47,XXY [2x], 47,XXX, 48,XXXX), one had a heterozygous complex rearrangement including SHOX gene duplication, and one carried a pathogenic variant in the TGFBR2 gene leading to Loeys–Dietz syndrome. A genetic cause of tall stature was significantly less common in nFTS (11%) than in our previously published cohort with FTS (32%). Conclusion: Cytogenetic abnormalities were the predominant genetic alteration identified in children with nFTS, confirming the justification of karyotype analysis in this cohort. The probability of genetic alterations was greater in children with FTS than in those with nFTS. Our findings suggest that the current guidelines for complex investigation are efficient for children with nFTS but need revision in children with FTS. What is known – what is new• Although tall stature is generally considered beneficial, it can be associated with health risks which need to be recognized in time. Tall stature without intellectual impairment is usually considered to be polygenic.• However, the cause of familial tall stature was monogenic more often than it was thought previously.• Children with non-familial and apparently non-syndromic tall stature have never been systematically investigated.• Monogenic causes of non-familial tall stature were observed in 11% of patients, including a participant with Loeys–Dietz syndrome.
- 17 June 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (7) , 1-9
Open AccessCytogenetic anomalies are the predominant genetic alteration in children with nonfamilial tall stature: a comparative study with familial cases
The purpose of this study is to elucidate the genetic causes and phenotypic presentation of nonfamilial tall stature (nFTS) and to compare these findings with those of familial tall stature (FTS) from the same population that was previously studied. Children with nFTS (defined as a height > + 2 SDs with both parents’ heights < + 2 SDs) underwent endocrine and anthropometric examinations and genetic testing (karyotyping, SHOX gene dosage analysis and next-generation sequencing of 786 growth-associated genes). Exome sequencing was performed in patients with negative genetic results and a height > + 3 SDs. A total of 55 children with nFTS were enrolled. The median height was + 2.8 SD (2.4–3.2 SD), and the median midparental height was + 0.7 SD (0.4–0.9 SD). Genetic causes of tall stature were identified in 6/55 (11%) children. Specifically, four children had gonosomal aneuploidy (47,XXY [2x], 47,XXX, 48,XXXX), one had a heterozygous complex rearrangement including SHOX gene duplication, and one carried a pathogenic variant in the TGFBR2 gene leading to Loeys–Dietz syndrome. A genetic cause of tall stature was significantly less common in nFTS (11%) than in our previously published cohort with FTS (32%). Conclusion: Cytogenetic abnormalities were the predominant genetic alteration identified in children with nFTS, confirming the justification of karyotype analysis in this cohort. The probability of genetic alterations was greater in children with FTS than in those with nFTS. Our findings suggest that the current guidelines for complex investigation are efficient for children with nFTS but need revision in children with FTS. What is known – what is new• Although tall stature is generally considered beneficial, it can be associated with health risks which need to be recognized in time. Tall stature without intellectual impairment is usually considered to be polygenic.• However, the cause of familial tall stature was monogenic more often than it was thought previously.• Children with non-familial and apparently non-syndromic tall stature have never been systematically investigated.• Monogenic causes of non-familial tall stature were observed in 11% of patients, including a participant with Loeys–Dietz syndrome.
- 2 April 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 27 (4) , 301-307
The Longer, the Better: Continuous Glucose Monitoring Use for ≥90% Is Superior to 70%–89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes
Objective: The recommended threshold for the time spent on continuous glucose monitoring (CGM) is established at 70%. However, glucose outcomes in children with type 1 diabetes (CwD) using CGM for a different proportion of time within this threshold have not been evaluated yet. The study aims to compare glycemic parameters among CwD who spent 70%–89% and ≥90% on CGM using the population-wide data from the Czech national pediatric diabetes registry ČENDA. Methods: CwD aged 70% of the time and did not change the type of therapy throughout the year 2023 were included and divided into two groups based on the time they spent on CGM—70%–89% versus ≥90%. HbA1c, times in standard glycemic ranges, mean glucose, and coefficient of variability (CV) were compared between the groups and by treatment modalities. Results: Data from 1977 CwD (1035 males and 942 females) were evaluated. Among them, 404 participants (20.4%) used CGM 70%–89% of the time, and 1573 participants (79.6%) ≥90% of the time. Compared with the 70–89% group, the ≥90% CGM users achieved significantly lower HbA1c levels (51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, P < 0.001), higher time in range (72% vs. 60%, P < 0.001), and lower mean glucose and CV (8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL and 37% vs. 40%, respectively, both P < 0.001). Analogous results were seen irrespective of the treatment modality. The differences persisted after propensity score adjustment. Conclusion: CGM use for ≥90% is associated with tighter glycemic control compared with 70%–89% use. Therefore, it is essential to motivate CwD to use CGM for the longest possible time and search for suitable options to overcome barriers in uninterrupted CGM monitoring.
- 2 April 2025
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 27 (4) , 301-307
The Longer, the Better: Continuous Glucose Monitoring Use for ≥90% Is Superior to 70%–89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes
Objective: The recommended threshold for the time spent on continuous glucose monitoring (CGM) is established at 70%. However, glucose outcomes in children with type 1 diabetes (CwD) using CGM for a different proportion of time within this threshold have not been evaluated yet. The study aims to compare glycemic parameters among CwD who spent 70%–89% and ≥90% on CGM using the population-wide data from the Czech national pediatric diabetes registry ČENDA. Methods: CwD aged 70% of the time and did not change the type of therapy throughout the year 2023 were included and divided into two groups based on the time they spent on CGM—70%–89% versus ≥90%. HbA1c, times in standard glycemic ranges, mean glucose, and coefficient of variability (CV) were compared between the groups and by treatment modalities. Results: Data from 1977 CwD (1035 males and 942 females) were evaluated. Among them, 404 participants (20.4%) used CGM 70%–89% of the time, and 1573 participants (79.6%) ≥90% of the time. Compared with the 70–89% group, the ≥90% CGM users achieved significantly lower HbA1c levels (51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, P < 0.001), higher time in range (72% vs. 60%, P < 0.001), and lower mean glucose and CV (8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL and 37% vs. 40%, respectively, both P < 0.001). Analogous results were seen irrespective of the treatment modality. The differences persisted after propensity score adjustment. Conclusion: CGM use for ≥90% is associated with tighter glycemic control compared with 70%–89% use. Therefore, it is essential to motivate CwD to use CGM for the longest possible time and search for suitable options to overcome barriers in uninterrupted CGM monitoring.
- Open Access
- 19 March 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (6) , 1101-1107
The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes
Early detection of type 1 diabetes, in its presymptomatic stage, offers significant clinical advantages, including treatment that can delay disease onset. Current screening focuses on identifying islet autoantibody positivity, with proposed optimal testing at ages 2, 6 and 10 years potentially achieving up to 80% sensitivity. However, challenges arise from participation rates and costs associated with multiple screenings. Genetic pre-screening has been suggested as a complementary strategy to target high-risk individuals prior to autoantibody testing, but its real-world benefits remain uncertain. Broad genetic selection strategies, based on family history, HLA typing or polygenic risk scores, can identify subsets of the population at elevated risk. However, these approaches face issues like low recall rates, socioeconomic biases and limited applicability across diverse ancestries. Additionally, the cost-effectiveness and infrastructure requirements of integrating genetic testing into routine healthcare remain significant hurdles. The combined use of genetic and autoantibody testing could improve predictive value, especially with innovations like point-of-care genetic testing. Yet, the ultimate success of any screening programme depends less on specific strategies and more on maximising public and healthcare-provider engagement, ensuring high participation, and addressing socioeconomic and demographic disparities. Digital-health infrastructure may play a crucial role in improving recall rates and maintaining follow-up adherence. In conclusion, while repeated islet autoantibody screening remains the most effective standalone approach, conducting genetic screening prior to islet autoantibody testing may be practical in certain contexts, provided that sufficient resources and equitable strategies are employed. Public engagement and robust infrastructure are essential to realising the full potential of early type 1 diabetes detection programmes. Graphical Abstract
- 19 March 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (6) , 1101-1107
Open AccessThe efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes
Early detection of type 1 diabetes, in its presymptomatic stage, offers significant clinical advantages, including treatment that can delay disease onset. Current screening focuses on identifying islet autoantibody positivity, with proposed optimal testing at ages 2, 6 and 10 years potentially achieving up to 80% sensitivity. However, challenges arise from participation rates and costs associated with multiple screenings. Genetic pre-screening has been suggested as a complementary strategy to target high-risk individuals prior to autoantibody testing, but its real-world benefits remain uncertain. Broad genetic selection strategies, based on family history, HLA typing or polygenic risk scores, can identify subsets of the population at elevated risk. However, these approaches face issues like low recall rates, socioeconomic biases and limited applicability across diverse ancestries. Additionally, the cost-effectiveness and infrastructure requirements of integrating genetic testing into routine healthcare remain significant hurdles. The combined use of genetic and autoantibody testing could improve predictive value, especially with innovations like point-of-care genetic testing. Yet, the ultimate success of any screening programme depends less on specific strategies and more on maximising public and healthcare-provider engagement, ensuring high participation, and addressing socioeconomic and demographic disparities. Digital-health infrastructure may play a crucial role in improving recall rates and maintaining follow-up adherence. In conclusion, while repeated islet autoantibody screening remains the most effective standalone approach, conducting genetic screening prior to islet autoantibody testing may be practical in certain contexts, provided that sufficient resources and equitable strategies are employed. Public engagement and robust infrastructure are essential to realising the full potential of early type 1 diabetes detection programmes. Graphical Abstract
- 14 March 2025
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 38 (5) , 525-532
Early-onset growth hormone treatment in Prader–Willi syndrome attenuates transition to severe obesity
Objectives: Subsequent to early life feeding issues, children with Prader–Willi syndrome (PWS) develop hyperphagia and severe obesity. Growth hormone (GH) therapy has been approved in PWS to improve growth, body composition, and BMI. We aimed to clarify the role of age at GH therapy onset on growth and BMI trajectories in children with PWS. Methods: We analyzed height and BMI in 114 patients (58 boys) from REPAR – Czech national GH registry. From them, 69 started GH therapy prior to 2 y/o (age 0.8 ± 0.4 years; mean ± SD; early-onset group [EO]), and 45 later (age 7.1 ± 4.1 years; late-onset group [LO]). Results: Height-SDS before therapy was similar in all (EO: −1.9 ± 1.2 [mean ± SD]; LO: −1.7 ± 1.1). After the first year of GH therapy, height-SDS in the EO group increased to −1.0 ± 1.2, in the LO group to −0.9 ± 1.1. After 5 years, height fully normalized in all (−0.1 ± 1.1 SDS). The LO children were already obese at treatment initiation (BMI-SDS: 2.9 ± 2.2), and their BMI-SDS decreased after 1 year of GH therapy by 0.9 (p=0.003). The weight in EO children was below average before GH treatment (BMI-SDS: −0.9 ± 1.2) and their BMI-SDS increased to the overweight range of 1.3 ± 2.2 (p<0.001) within the oncoming 3 years. Albeit BMI-SDS was around the obesity limit in most children after 5 years on GH therapy, the highest lifetime BMI-SDS was lower in EO (2.2 ± 2.6) than in LO (3.7 ± 2.2; p<0.001). Conclusions: GH treatment in PWS normalizes body height. After 5 years of GH therapy, BMI-SDS in EO and LO groups are similar; however, the EO group is exposed to lower maximal BMI-SDS values.
- 14 March 2025
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 38 (5) , 525-532
Early-onset growth hormone treatment in Prader–Willi syndrome attenuates transition to severe obesity
Objectives: Subsequent to early life feeding issues, children with Prader–Willi syndrome (PWS) develop hyperphagia and severe obesity. Growth hormone (GH) therapy has been approved in PWS to improve growth, body composition, and BMI. We aimed to clarify the role of age at GH therapy onset on growth and BMI trajectories in children with PWS. Methods: We analyzed height and BMI in 114 patients (58 boys) from REPAR – Czech national GH registry. From them, 69 started GH therapy prior to 2 y/o (age 0.8 ± 0.4 years; mean ± SD; early-onset group [EO]), and 45 later (age 7.1 ± 4.1 years; late-onset group [LO]). Results: Height-SDS before therapy was similar in all (EO: −1.9 ± 1.2 [mean ± SD]; LO: −1.7 ± 1.1). After the first year of GH therapy, height-SDS in the EO group increased to −1.0 ± 1.2, in the LO group to −0.9 ± 1.1. After 5 years, height fully normalized in all (−0.1 ± 1.1 SDS). The LO children were already obese at treatment initiation (BMI-SDS: 2.9 ± 2.2), and their BMI-SDS decreased after 1 year of GH therapy by 0.9 (p=0.003). The weight in EO children was below average before GH treatment (BMI-SDS: −0.9 ± 1.2) and their BMI-SDS increased to the overweight range of 1.3 ± 2.2 (p<0.001) within the oncoming 3 years. Albeit BMI-SDS was around the obesity limit in most children after 5 years on GH therapy, the highest lifetime BMI-SDS was lower in EO (2.2 ± 2.6) than in LO (3.7 ± 2.2; p<0.001). Conclusions: GH treatment in PWS normalizes body height. After 5 years of GH therapy, BMI-SDS in EO and LO groups are similar; however, the EO group is exposed to lower maximal BMI-SDS values.